SynthesisFrontiers in immunology2026
Perioperative immunochemotherapy for resectable gastric or gastroesophageal junction cancer: a meta-analysis of efficacy and safety from randomized trials.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy and safety of perioperative immune checkpoint inhibitors (ICIs) combined with chemotherapy for resectable gastric/gastroesophageal junction (GEJ) cancer remain to be definitively established. This meta-analysis aimed to synthesize the latest evidence from randomized controlled trials (RCTs) on this emerging therapeutic strategy. Methods: A systematic literature search was conducted in PubMed, Embase, and the Cochrane Library up to June 2026 for RCTs comparing perioperative ICI plus chemotherapy with chemotherapy alone in patients with resectable gastric/GEJ cancer. Primary outcomes included pathological complete response (pCR), R0 resection rate, and survival endpoints (event-free survival [EFS] and overall survival [OS]). Safety was assessed by the incidence of adverse events. Pooled risk ratios (RRs), hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated using random-effects models. Results: Seven RCTs comprising 3252 patients were included. The addition of ICIs to chemotherapy significantly improved the pCR rate compared to chemotherapy alone (RR: 2.91, 95% CI: 2.16 to 3.93, Conclusion: This meta-analysis provides updated evidence that the addition of ICIs to perioperative chemotherapy significantly enhances pathological responses and survival outcomes in patients with resectable gastric/GEJ cancer, with a safety profile that showed no statistically significant difference in adverse events compared to chemotherapy alone. These results further reinforce the use of perioperative ICI-chemotherapy combination as a promising treatment strategy for this patient population, although confirmation in larger trials with longer follow-up is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.